Key findings

It is difficult to predict the extent to which ‘personalised medicines’ will become a reality. Claims of designer drugs, or ‘the right medicine, for the right patient, at the right dose’ are misleading, but it is important to discuss ethical, legal, regulatory and social issues that may be raised by improvements in predicting response to medicines.

To obtain maximum benefits from pharmacogenetics we need to address legitimate concerns and safeguard against inappropriate use. There must be the right combination of constraints and incentives to protect and promote the interests of patients and society as pharmacogenetic testing is more widely introduced.

row of pill bottles

Previous work

Contact us

Nuffield Council on Bioethics
28 Bedford Square
London
WC1B 3JS

bioethics@nuffieldbioethics.org

+44 (0)20 7681 9619

Get regular e-news

Community

Explore by topic